Last reviewed · How we verify

NCT04416217: EESY

Eosinophilic Esophagitis Steroid Safety Study

Completed Last updated 7 May 2025
What this trial tests

trial in Eosinophilic Esophagitis in 55 participants. Completed in 31 December 2024.

Timeline
7 October 2019
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorRabin Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment55
Start date7 October 2019
Primary completion31 December 2024
Estimated completion31 December 2024
Sites4 locations across Italy, Israel, Greece

Conditions studied

Sponsor

Rabin Medical Center

Who can join

Under 18, any sex, with Eosinophilic Esophagitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational study will follow pediatric patients with eosinophilic esophagitis who are scheduled to begin topical steroid treatment, from the initiation of treatment longitudinally to determine the safety profile of the drug.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Eosinophilic Esophagitis

Currently open trials in the same condition.

Other Rabin Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04416217.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing